^
Association details:
| Biomarker: | KIT mutation |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
03/13/2023
Excerpt:
Gastrointestinal Stromal Tumor….Systemic Therapy Agents and Regimens for GIST...Preferred regimens: Imatinib for KIT or PDGFRA mutations (excluding PDGFRA exon 18 mutations that are insensitive to imatinib, including D842V).
Source:
Title:
Imatinib TDM in GIST
Excerpt:
...- Histologically or cytologically confirmed GIST with KIT mutation or PDGFRA mutation (non-D842V)...
Trial ID:
Source:
Title:
Ipilimumab and Imatinib Mesylate in Advanced Cancer
Excerpt:
...For expansion cohorts, patients must have metastatic or unresectable gastrointestinal stromal tumor (GIST), melanoma, or uncategorized tumors with tumor biopsies that are positive for c-KIT mutations by polymerase chain reaction (PCR) or immunohistochemistry (IHC)....
Trial ID:
More C2 evidence
Source:
Title:
Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI
Excerpt:
...- Histologically confirmed metastatic or unresectable GIST with CD117(+), DOG-1 (+), or KIT mutation...
Trial ID:
Source:
Title:
Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST
Excerpt:
...C-KIT gene mutation....
Trial ID:
Source:
Title:
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
Excerpt:
...Histologically confirmed GIST with CD117(+), DOG-1(+), or mutation in KIT or PDGFRα gene 3....
Trial ID:
Source:
Title:
A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs
Excerpt:
...- Patients with metastatic or unresectable GIST which has been histologically confirmed by the detection of CD117 on immunohistochemical staining or genetically confirmed by the detection of mutation in KIT or PDGFRα genes on direct sequencing of tumor DNA....
Trial ID:
Source:
Title:
Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors
Excerpt:
...- Gene mutation test report including c-kit exons 9,11,13 and 17 and platelet-derived growth factor receptor alpha (PDGFRA) exons 12 and 18...
Trial ID:
Source:
Title:
Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258
Excerpt:
...- Histologically confirmed metastatic and/or advanced GIST with CD117(+), DOG-1(+), or mutation in KIT or PDGFRα gene...
Trial ID:
Source:
Title:
Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT
Excerpt:
...- Patients with metastatic or unresectable malignant gastrointestinal stromal tumour which has been histologically confirmed by the detection of CD117 on immunohistochemical staining or genetically confirmed by the detection of mutation in KIT or PDGFRα genes on direct sequencing of tumor DNA....
Trial ID:
Source:
Title:
Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor
Excerpt:
...- Histologically confirmed metastatic and/or advanced (unresectable or recurrent) GIST with CD117(+), DOG-1(+), or mutation in KIT or PDGFRα gene...
Trial ID:
Source:
Title:
Jejunoileal vs Gastric GIST in the Era of Imatinib.
Excerpt:
...Number of patients with a molecular analysis positive for KIT mutation`KIT Gene mutation`Number of patients with a molecular analysis positive for PDGFRA mutation`PDGFRA Gene mutation`Number of patients with immunohistochemical expression of CD117`Expression of CD117`Number of patients with immunohistochemical expression of DOG1`Expression of DOG1`Number of patients with recurrence after treatment with tyrosinkin inhibitors.`...
Trial ID:
Source:
Title:
Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
Excerpt:
...- Metastatic and/or locally advanced GIST, with diagnosis based on histology with positive c-kit and/or DOG-1, or with a GIST-typical mutation in KIT or PDGFR...
Trial ID:
Source:
Title:
Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate
Excerpt:
...- Histologically confirmed gastrointestinal stromal tumor expressing CD117+ or with documented mutation of the KIT or PDGFRA gene...
Trial ID:
Source:
Title:
A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients
Excerpt:
...Patients with histologically proven CD117-positive and/or c-kit or PDGFR mutation gastrointestinal stromal tumor (GIST), which is metastatic or unresectable, locally advanced, and have failed to or intolerance of prior imatinib and sunitinib treatment 2....
Trial ID:
Source:
Title:
Role of surgery in patients with resectable liver metastases from GISTs: a prospective, single-center, real-world study
Excerpt:
...Mutations are detected in c-kit or PDGFRα (not exon 18 D842V) using samples from biopsy or surgical specimens; 5. ...
Trial ID:
Source:
Title:
Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation
Excerpt:
...- Presence of mutation in exon 11 of c-kit gene....
Trial ID:
Source:
Title:
Adjunction of cilostazol to imatinib for patients with an unresectable or metastatic GIST (Gatsrointestinal stromal tumor) already treated by imatinib or who will start a treatment with imatinib Association du cilostazol à l’imatinib pour le traitement des GIST (GastroIntestinal Stromal Tumor) non résécables et ou métastatiques nécessitant un traitement par imatinib ou déjà traités par imatinib
Excerpt:
...Inclusion Criteria: -histologically proven metastatic or locally advanced histologically proven non resectable GIST ( any primary tumor site) already treated by Glivec® (at any dose) for at least 12 months in first line therapy, or patients who will start Glivec® (at any dose) in first line therapy or after failure of all TKIs -exon 11, exon 9 or other kit mutations -written signed informed consent -ability to take oral medication -metabolic positivity of the tumor at the first PET-CT (positivity is defined as High 18F-FDG uptake by a lesion more than the surrounding tissue) -at least one measurable lesion by CT scanner -no contraindication to cilostazol -ECOG performance status 0 /1 at study entry -effective contraception for both male and female patients must be used for at least 8 weeks after the last study drug administration if the risk of conception exists -age > 18 years old -life expectancy at least 12 weeks - Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements conducted within 7 days of starting to study treatment: o Serum creatinine ...
Trial ID:
Less C2 evidence
Source:
Title:
The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice
Published date:
08/16/2020
Excerpt:
The majority of GIST cases harboured exon 11 KIT mutations (88 cases, 82%), 11 cases had exon 9 KIT mutations (10%), 8 had other KIT/PDGFRA mutations potentially sensitive to imatinib. The disease relapse was detected in 19 patients, of them in 5 cases in exon 9 KIT mutants (45%), and 14 cases in patients with exon 11 KIT mutations (11%) [p < 0.01].
DOI:
10.1016/j.ejso.2020.08.004
